Plasma-derived exosomes from healthy and osteosarcoma
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Blood Plasma, Blood
SUBMITTER: 
Zhenzhen Han
LAB HEAD: Liang Qiao
PROVIDER: PXD024072 | Pride | 2021-07-02
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Fusion_20191218_60min_Con_1.raw | Raw | |||
| Fusion_20191218_60min_Con_2.raw | Raw | |||
| Fusion_20191218_60min_Con_3.raw | Raw | |||
| Fusion_20191218_60min_Met_1.raw | Raw | |||
| Fusion_20191218_60min_Met_2.raw | Raw |
Items per page: 5 1 - 5 of 9 |
Similar Datasets
Project description:In order to identify the targets of miR-193a-5p in osteosarcoma U2OS cell line, we used a lentivirus-mediated expression system to overexpressing miR-193a precusor, miR-193a-5p target sequence and non-target sequence, respectively, in osteosarcoma cell line U2OS. A tandem mass tag (TMT)-based quantitative proteomic strategy was employed to identify the global profile of miR-193a-5p-regulated proteins. order to identify the targets of miR-193a-5p, we used a lentivirus-mediated expression system to overexpressing miR-193a precusor, miR-193a-5p target sequence and non-target sequence, respectively, in osteosarcoma cell line U2OS. A tandem mass tag (TMT)-based quantitative proteomic strategy was employed to identify the global profile of miR-193a-5p-regulated proteins.
2021-09-08 | PXD013987 | Pride
Project description:Lobaplatin is a third-generation platinum-based antineoplastic agent and is widely used for osteosarcoma treatment before and after tumor removal. However, treatment failure often results from lobaplatin drug resistance. In our study, we found that SaOS-2 and SOSP-9607 osteosarcoma cells became less sensitive to lobaplatin after treatment with exogenous interleukin (IL)-6. Quantitative proteomic analysis was performed to elucidate the underlying mechanism in SaOS-2 osteosarcoma cells. Cells were divided into a control group (CG), a lobaplatin treatment group (LG) and a recombinant human IL-6 (rhIL-6) and lobaplatin group (rhILG). We performed three biological replicates in each group to compare the differential protein expression between groups using tandem mass tag (TMT) labeling technology based on liquid chromatography–tandem mass spectrometry (LC-MS/MS). A total of 1,313 proteins with significantly differential expression were identified and quantified. The general characterizations of significantly enriched proteins were identified by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, and protein-protein interaction (PPI) analysis was conducted using IntAct and STRING. In total, 31 proteins were further verified by parallel reaction monitoring (PRM), in which Ras GTPase-activating protein-binding protein 1 (G3BP1), fragile X mental retardation syndrome-related protein 1 (hFXR1p) and far upstream element-binding protein 1 (FUBP1) were significantly differentially expressed. Immunohistochemistry results showed that these three proteins are highly expressed in specimens of platinum-resistant osteosarcoma patients, while the proteins are negatively or weakly expressed in specimens of platinum-sensitive osteosarcoma patients. The results of immunofluorescence staining were in accordance with those of immunohistochemistry staining. This is the first proteomic study on rhIL-6 intervention before lobaplatin treatment in osteosarcoma cells.
2021-02-25 | PXD021564 | Pride
Project description:Our study aimed to adopt a proteomics strategy for analysing changes in the levels of proteins between PTC and para-tumour specimens. A integrative strategy was adopted to identify the important pathways in PTC.
2021-12-14 | PXD027538 | Pride
Project description:Gain or loss of genes and deregulation of gene expression can result in cumulative and progressive disruptions of normal cellular functions. Cancer-specific changes in gene expression play an essential role in cancer occurrence, and ultimately lead to cancer-related self-sufficiency in growth signals, insensitivity to growth inhibitory signals, evasion of apoptosis, limitless replicative potential, angiogenesis, and metastasis. We aimed to analyse such changes in gene expression related to osteosarcoma. We performed genome-wide comparison of gene expression and identified genes that are differentialy expressed in osteosarcoma tumour samples relative to normal human osteoblasts (HOB)
2010-04-09 | E-GEOD-12865 | biostudies-arrayexpress
Project description:Syndecan-2 was found to act as a tumor suppressor in osteosarcoma and to mediate the apoptotic response to cytotoxic agents. To determine new mechanisms that control cell survival and apoptosis in osteosarcoma cells, we aim to show target genes that are involved downstream of this proteoglycan during apoptosis induction. We aim to compare the modifications induced by syndecan-2 overexpression in two different human osteosarcoma cell lines using a lentiviral vector coding the human syndecan-2. Syndecan-2 lentiviral vector (SY) and control empty lentiviral vector (VV) were transducted in two different human osteosarcoma cell lines in a dye-swap experiment.
2013-09-23 | E-GEOD-19913 | biostudies-arrayexpress
Project description:Gain or loss of genes and deregulation of gene expression can result in cumulative and progressive disruptions of normal cellular functions. Cancer-specific changes in gene expression play an essential role in cancer occurrence, and ultimately lead to cancer-related self-sufficiency in growth signals, insensitivity to growth inhibitory signals, evasion of apoptosis, limitless replicative potential, angiogenesis, and metastasis. We aimed to analyse such changes in gene expression related to osteosarcoma. Keywords: Comparative We performed genome-wide comparison of gene expression and identified genes that are differentialy expressed in osteosarcoma (U2OS, MG63) cell lines relative to normal human osteoblasts (HOB)
2009-05-01 | E-GEOD-11414 | biostudies-arrayexpress
Project description:Epigenetic change of genes expression, including hypomethylation-linked activation of oncogenes and hypermethylation-associated inactivation of tumor suppressor genes, can affect almost all the cellular signaling pathways that participate in cancer initiation and progression. Unlike genetic alterations, epigenetic changes are potentially reversible, making them attractive and promising targets for therapeutic intervention. Studies indicated that abnormal DNA methylation is involved in dysregulation of cell cycle, apoptosis, proliferation and differentiation of osteosarcoma. However, epigenetic mechanisms of osteosarcoma metastasis remain largely unknown. MeDIP chips are performed in ZOS and ZOSM—two syngeneic primary human osteosarcoma cell lines with low and high metastatic potential which are established in our lab
2015-08-25 | E-GEOD-55961 | biostudies-arrayexpress
Project description:IL-6 plays a pivotal role in the process of drug resistance to kinds of chemotherapeutics including lobaplatin. However, the underlying changes of phosphoproteins and related signaling pathways in the posttranslational modification level is still uncover. In our study, a quantitative phosphoproteome analysis of the responses to rhIL-6 & lobaplatin treatment was performed in osteosarcoma cells. Cells were divided into three goups: the control group, the lobaplatin group, and the rhIL-6 & lobaplatin group. Three biological replicates were performed in each group. A total of 3373 proteins and 12183 peptides was identified and quantified, of which 3232 phosphorylated proteins and 11358 phosphorylated peptides were obtained. Between the rhIL-6 & lobaplatin group and the lobaplatin group, twenty-three statistically differentially expressed phosphorylated peptides were identified. The characteristics of differentially expressed phophoproteins were analyzed by GO and KEGG enrichment, kinases of the phosphoproteins were predicted and protein-protein interaction was illustrated/demonstrated using STRING. Conservative motifs that surround the phosphorylated serine, threonine and tyrosine residues were analyzed using the Motif-x algorithm. Western blotting were performed to verify the differentially expressed phosphorylated FLNC and the signaling pathway it involved in. Immunohistochemistry staining showed that p-FLNC and its kinase AKT1 as well as ERK1/2 are positively expressed in the platinum-resistant specimens, while these proteins are negative or weak in those of platinum-sensitive specimens. In conclusion, p-FLNC and the MAPK signaling pathway plays a crucial role in the process of IL-6 induced chemoresistance in osteosarcoma. It is the first phosphoproteomic study which reveals the signature of IL-6 intervention before lobaplatin treatment in human osteosarcoma cells.
2022-02-17 | PXD025970 | Pride
Project description:Paget's associated osteosarcoma
| PRJNA343233 | ENA
Project description:expression analysis from a genetically engineered mouse model of osteosarcoma determine the expression profile of mouse osteosarcoma Keywords: disease state analysis
2008-06-15 | GSE9460 | GEO